After two years of a quiet IPO window, the biotech markets are showing renewed signs of life. A growing number of companies are testing public waters again — but with tighter investor scrutiny, leaner balance sheets, and a renewed emphasis on clinical proof and capital efficiency. This panel brings together investors, bankers, and CEOs who have recently navigated or are preparing for the public markets. They will discuss what differentiates companies that can succeed in today’s IPO climate, how crossover financing is being used to de-risk listings, and what private biotech leaders should know as they plan for the next wave of market openings. Attendees will learn how macroeconomic forces, therapeutic focus areas, and valuation trends are shaping deal timing and investor appetite in 2026.